LipoSwift LNP - In Vivo Liver-Targeting Kit

The in vivo series is developed using proprietary lipid nanoparticle (LNP) technology, systematically designed to meet diverse in vivo nucleic acid application needs, achieving high delivery efficiency, precise targeting, and excellent biocompatibility. One of the key features of this series of kits is its ease of use while maintaining a high transfection efficiency. It is designed for a simple, single-step encapsulation process that does not require any specific LNP encapsulation equipment.

The LipoSwift LNP – In Vivo Liver-Targeting Kit is an advanced LNP formulation designed to achieve highly efficient and selective delivery of nucleic acids to the liver in vivo. The liver is a central organ for a vast number of physiological processes, making it a prime target for therapeutic intervention. Liver-specific gene delivery is essential for treating a wide array of conditions, including genetic disorders like hemophilia and alpha-1 antitrypsin deficiency, metabolic diseases such as familial hypercholesterolemia, and infectious diseases like chronic hepatitis B. However, delivering nucleic acid payloads specifically to the liver has historically been a significant challenge. Traditional delivery systems often result in non-specific biodistribution, leading to off-target effects and reduced therapeutic efficacy. Through a finely tuned formulation and a patented lipid composition, our kit achieves exceptionally high and selective accumulation of the LNP-nucleic acid complex in the hepatic tissue following administration. From basic liver biology to preclinical therapeutic development, this kit provides the reliability, reproducibility, and flexibility required to accelerate discovery. Whether you are working on metabolic disorders, liver cancer, or gene therapy, the kit enables you to translate your ideas into impactful in vivo experiments with unmatched convenience.

• High Liver-Specific Targeting: The LNP composition has been engineered to ensure preferential biodistribution to hepatocytes while minimizing off-target accumulation. This highly refined targeting mechanism ensures that a maximum amount of the nucleic acid payload reaches its intended destination.
• Broad Payload Compatibility: The kit can encapsulate various nucleic acid formats, including mRNA, siRNA, saRNA, circRNA, and shRNA, enabling a wide range of applications in basic research and therapeutic development.
• Single-Step Encapsulation Without Special Equipment: The kit enables encapsulation in one simple step using standard laboratory pipettes, drastically reducing the time and cost associated with LNP preparation.
• High Transfection Efficiency: Performance benchmarks show that LNPs prepared with this kit achieve transfection efficiencies comparable to LNPs made with professional encapsulation systems, ensuring that researchers do not compromise on data quality when opting for simplicity.
• Excellent Biocompatibility: The proprietary lipid composition of LipoSwift nanoparticles is optimized for low immunogenicity and high stability in physiological environments, ensuring minimal adverse effects and better tolerability in vivo.

The exceptional performance of the LipoSwift LNP - In Vivo Liver-Targeting Kit is supported by extensive data. A key demonstration of the kit's efficacy involves the delivery of a luciferase-encoding RNA to a murine model, showcasing highly specific gene expression in the liver.

LipoSwift LNP - In Vivo Liver-Targeting Kit User Manual